Figure 1.

AOS pretreatment attenuates doxorubicin (DOX)-induced cardiac contractile dysfunction. (A) Cardiac function of mice receiving DOX injection with or without AOS pretreatment (200 mg/kg/day, 7 days) was measured after five days, and representative echocardiographic images were acquired; (B–E) Cardiac function was measured after five days. LVEDD: left ventricular end-diastolic dimension; LVESD: left ventricular end-systolic dimension; EF: left ventricular ejection fraction; FS: left ventricular fractional shortening. * p < 0.05 vs. the control (CON) group; ^# p < 0.05 vs. the CON + DOX group, n = 6 in each group.